Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CTXR Stock Forecast 2025-2026
$1.18
Current Price
$21.80M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CTXR Price Targets
+408.5%
To High Target of $6.00
+408.5%
To Median Target of $6.00
+408.5%
To Low Target of $6.00
CTXR Price Momentum
-18.1%
1 Week Change
-5.6%
1 Month Change
-66.5%
1 Year Change
-70.5%
Year-to-Date Change
-80.2%
From 52W High of $5.95
+81.5%
From 52W Low of $0.65
📊 TOP ANALYST CALLS
Did CTXR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Citius is one of their latest high-conviction picks.
Latest CTXR Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CTXR has a neutral consensus with a median price target of $6.00 (ranging from $6.00 to $6.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.18, the median forecast implies a 408.5% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 408.5% upside. Conversely, the most conservative target is provided by Jason Kolbert at D. Boral Capital, suggesting a 408.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTXR Analyst Ratings
1
Buy
1
Hold
0
Sell
CTXR Price Target Range
Low
$6.00
Average
$6.00
High
$6.00
Current: $1.18
Latest CTXR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTXR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 4, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $6.00 |
| Aug 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $6.00 |
| Jun 30, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $6.00 |
| Jun 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $6.00 |
| Jun 9, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| May 23, 2025 | Maxim Group | Jason McCarthy | Hold | Downgrade | $N/A |
| May 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| Feb 18, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| Jan 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| Dec 30, 2024 | D. Boral Capital | Jason Kolbert | Buy | Upgrade | $9.00 |
| Nov 22, 2024 | D. Boral Capital | Jason Kolbert | Hold | Downgrade | $N/A |
| Nov 12, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $4.00 |
| Nov 11, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $6.00 |
| Aug 19, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $6.00 |
| Aug 8, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $6.00 |
| Aug 5, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $6.00 |
| Jul 15, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $6.00 |
| May 31, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $4.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $4.00 |
| Aug 10, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $4.00 |
Citius Pharmaceuticals, Inc. (CTXR) Competitors
The following stocks are similar to Citius based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CTXR
Citius Pharmaceuticals
mkt cap
21.80M
Citius Pharmaceuticals, Inc. (CTXR) Financial Data
Citius Pharmaceuticals, Inc. has a market capitalization of $21.80M with a P/E ratio of -0.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -54.7%.
Valuation Metrics
Market Cap
$21.80M
Enterprise Value
$18.37M
P/E Ratio
-0.2x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+30.3%
Current Ratio
0.5x
Debt/Equity
2.8x
ROE
-54.7%
ROA
-22.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Citius Pharmaceuticals, Inc. (CTXR) Business Model
About Citius Pharmaceuticals, Inc.
What They Do
Develops critical care biopharmaceutical products.
Business Model
Citius Pharmaceuticals operates as a late-stage biopharmaceutical company, focusing on the development and commercialization of innovative therapies in areas such as anti-infectives and oncology. The company generates revenue through the advancement of its drug candidates, targeting significant medical conditions and addressing unmet healthcare needs.
Additional Information
Headquartered in Cranford, New Jersey, Citius Pharmaceuticals emphasizes improving patient outcomes by leveraging clinical expertise to bring products through late-stage development towards commercialization.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
23
CEO
Mr. Leonard L. Mazur
Country
United States
IPO Year
2017
Website
citiuspharma.comCitius Pharmaceuticals, Inc. (CTXR) Latest News & Analysis
Latest News
Quick Summary
Citius Oncology has signed an exclusive distribution agreement to expand access to LYMPHIR for cutaneous T-cell lymphoma in several Middle Eastern countries and Turkey, increasing its market presence to 19 countries.
Why It Matters
The expansion of LYMPHIR's availability to 19 international markets enhances Citius Oncology's revenue potential and market presence, positively impacting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Oncology has launched LYMPHIR™ (denileukin diftitox-cxdl) nationwide, as announced on December 1, 2025. Citius Oncology is a subsidiary of Citius Pharmaceuticals.
Why It Matters
The nationwide launch of LYMPHIR™ signals potential revenue growth for Citius Oncology, enhancing investor confidence in its market position and future earnings.
Source: PRNewsWire
Market Sentiment:
Neutral
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
12 days ago
Quick Summary
Citius Oncology will showcase LYMPHIR™ at the ASH Annual Meeting in December 2025. The launch for LYMPHIR is scheduled for Q4 2025.
Why It Matters
Citius Oncology's upcoming product launch and exhibition at a major medical conference highlight its growth potential and market positioning, which could influence investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Oncology announces collaboration with Verix to enhance salesforce targeting for the upcoming launch of their cutaneous T-cell lymphoma immunotherapy.
Why It Matters
Citius Oncology's collaboration with Verix enhances its marketing strategy for a new immunotherapy, potentially improving sales and market position, which may positively impact stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Pharmaceuticals Inc. has engaged in a registered direct offering, selling 3,973,510 shares at $1.51 each, along with warrants for the same number of shares.
Why It Matters
Citius Pharmaceuticals' stock offering at $1.51 per share indicates potential dilution for existing shareholders but may raise funds for R&D, impacting future growth prospects and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Pharmaceuticals Inc. closed a registered direct offering, selling 3,973,510 shares at $1.51 each, along with common warrants for the same number of shares.
Why It Matters
Citius Pharmaceuticals' successful stock offering raises capital for development, potentially enhancing growth prospects and affecting share valuation, influencing investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CTXR Stock
What is Citius Pharmaceuticals, Inc.'s (CTXR) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Citius Pharmaceuticals, Inc. (CTXR) has a median price target of $6.00. The highest price target is $6.00 and the lowest is $6.00.
Is CTXR stock a good investment in 2026?
According to current analyst ratings, CTXR has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CTXR stock?
Wall Street analysts predict CTXR stock could reach $6.00 in the next 12 months. This represents a 408.5% increase from the current price of $1.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Citius Pharmaceuticals, Inc.'s business model?
Citius Pharmaceuticals operates as a late-stage biopharmaceutical company, focusing on the development and commercialization of innovative therapies in areas such as anti-infectives and oncology. The company generates revenue through the advancement of its drug candidates, targeting significant medical conditions and addressing unmet healthcare needs.
What is the highest forecasted price for CTXR Citius Pharmaceuticals, Inc.?
The highest price target for CTXR is $6.00 from Jason Kolbert at D. Boral Capital, which represents a 408.5% increase from the current price of $1.18.
What is the lowest forecasted price for CTXR Citius Pharmaceuticals, Inc.?
The lowest price target for CTXR is $6.00 from Jason Kolbert at D. Boral Capital, which represents a 408.5% increase from the current price of $1.18.
What is the overall CTXR consensus from analysts for Citius Pharmaceuticals, Inc.?
The overall analyst consensus for CTXR is neutral. Out of 4 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are CTXR stock price projections?
Stock price projections, including those for Citius Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 3:20 PM UTC